CrushSCI.com
114.4Average days
90Median days
55Fastest days
339Longest days
592025 publications

Paper Review Records

All Paper Review Records

11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

89 days

New ways of patient participation in clinical and translational cancer research

Authors
Wiebke Kragl; Jonathan P. Sleeman; Jörg HaierShow moreShow less
Affiliations
1. Universitätsmedizin Rostock; 2. Heidelberg University; 3. Medizinische Fakultät MannheimShow moreShow less
Source PDF DOI Publisher page
100 days

Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study

Authors
Alessandro Rizzo; Fernando Sabino Marques Monteiro; Veronica Mollica; Oronzo Brunetti; Elsa Vitale; Angela Monica Sciacovelli; Andrey Soares; Francesco Massari; Matteo SantoniShow moreShow less
Affiliations
1. S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy; 2. Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil; 3. Oncology and Hematology Department, Hospital Sírio-Libanês, Brasilia, Brazil; 4. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 5. Scientific Directorate, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy; 6. Hospital Israelita Albert Einstein, São Paulo, Brazil; 7. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; 8. Oncology Unit, Macerata Hospital, Macerata, ItalyShow moreShow less
Source PDF DOI Publisher page
157 days

Establishing patient-derived tumor organoids of bone metastasis from lung adenocarcinoma reveals the transcriptomic changes underlying denosumab treatment

Authors
Xianglin Hu; Huajian Wu; Kewen Hu; Yani Kang; Guoqiang Hua; Mo Cheng; Wangjun Yan; Wending HuangShow moreShow less
Affiliations
1. Department of Musculoskeletal Oncology, Spine Tumor Center, Fudan University Shanghai Cancer Center, Shanghai, China; 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; 3. Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen, China; 4. Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China; 5. Research and Early Development (RED) of D1 Medical Technology Company, Shanghai, ChinaShow moreShow less
Source PDF DOI Publisher page
339 days

Pulmonary lysyl oxidase expression and its role in seeding Lewis lung carcinoma cells

Authors
Kimberly J. Jasmer; Vinit C. Shanbhag; Kevin Muñoz Forti; Lucas T. Woods; Nikita S. Gudekar; Gary A. Weisman; Michael J. PetrisShow moreShow less
Affiliations
1. Christopher S. Bond Life Sciences Center 540F, University of Missouri, Columbia, USA; 2. Department of Biochemistry, University of Missouri, Columbia, USA; 3. Department of Ophthalmology, University of Missouri, Columbia, USAShow moreShow less
Source PDF DOI Publisher page
90 days

Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study

Authors
Alexander Fabian; Daniel Buergy; Fabian Weykamp; Juliane Hörner-Rieber; Denise Bernhardt; Judit Boda-Heggemann; Montserrat Pazos; Nora Mehrhof; David Kaul; Alicia S. Bicu; Eugenia Vlaskou Badra; Susanne Rogers; Stefan Janssen; Hossein Hemmatazad; Katharina Hintelmann; Eleni Gkika; Tim Lange; Konstantinos Ferentinos; Heiko Karle; Thomas Brunner; Andrea Wittig; Marciana Nona-Duma; Oliver Blanck; David KrugShow moreShow less
Affiliations
1. Department of Radiation Oncology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany; 2. Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany; 3. Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; 4. Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 5. Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany; 6. National Center for Tumor Diseases (NCT), Heidelberg, Germany; 7. Department of Radiation Oncology, University Hospital Düsseldorf, Düsseldorf, Germany; 8. Department of Radiation Oncology, Technical University of Munich, Munich, Germany; 9. Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; 10. Department of Radiation Oncology, Charité—Universitätsmedizin Berlin, Berlin, Germany; 11. Department of Radiation Oncology, Health and Medical University Potsdam, Potsdam, Germany; 12. Department of Radiation Oncology, University Hospital & University of Zurich, Zurich, Switzerland; 13. Radiation Oncology Center KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland; 14. Department of Radiation Oncology, University of Lubeck, Lubeck, Germany; 15. Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany; 16. Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 17. Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 18. Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany; 19. Department of Radiation Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany; 20. Clinic for Radiotherapy, Hannover Medical School, Hannover, Germany; 21. Department of Radiation Oncology, German Oncology Center, European University of Cyprus, Limassol, Cyprus; 22. Department of Radiation Oncology and Radiotherapy, University Medical Center, Mainz, Germany; 23. Department of Radiation Oncology, University Hospital Graz, Graz, Austria; 24. Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany; 25. Department of Radiation Oncology, HELIOS Hospital Schwerin, Schwerin, Germany; 26. Department for Human Medicine, MSH Medical School Hamburg, Hamburg, GermanyShow moreShow less
Source PDF DOI Publisher page
127 days

Current preclinical models of brain metastasis

Authors
Zacharie Drouin; Flavie Lévesque; Korina Mouzakitis; Marilyne LabrieShow moreShow less
Affiliations
1. Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada; 2. Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke (CRCHUS), Sherbrooke, Canada; 3. Institut de Recherche sur le Cancer de l’Université de Sherbrooke (IRCUS), Sherbrooke, CanadaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does CLINICAL & EXPERIMENTAL METASTASIS take to review a manuscript?

As of 2026-11-19, CrushSCI has 11 complete review records for CLINICAL & EXPERIMENTAL METASTASIS. The fastest paper went from submission to acceptance in 55 days (Multi-institutional study using sbrt to treat mediastinal and hilar lymphadenopathy, received 2024-08-06, accepted 2024-09-30); the slowest took 339 days. The average is 114.4 days and the median is 90 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.